Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
企業コードTEM
会社名Tempus AI Inc
上場日Jun 14, 2024
最高経営責任者「CEO」Mr. Eric P. Lefkofsky, J.D.
従業員数2400
証券種類Ordinary Share
決算期末Jun 14
本社所在地600 West Chicago Avenue
都市CHICAGO
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号60654
電話番号18009765448
ウェブサイトhttps://www.tempus.com/
企業コードTEM
上場日Jun 14, 2024
最高経営責任者「CEO」Mr. Eric P. Lefkofsky, J.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし